Thomas Schürpf

Thomas Schürpf

Company: Parthenon Therapeutics

Job title: Senior Director, Tumor Biology


Breaking Down Barriers In Immune-Excluded Tumor Biology 4:15 pm

Immune exclusion in tumors has been associated with unfavorable clinical outcome and poor response to therapy Therapies targeting immune exclusion are orthogonal to cancer immunotherapy and could improve responses DDR1 as an example of a druggable target implicated in establishing mechanical barriers for an immune responseRead more

day: Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.